Ruthless Prioritization and How it Can Help Every Medtech Startup: Interview With Paul Buckman Former CEO of Conventus, SentreHEART, and Pathway Medical Technologies

A few years ago, I had the privilege of sitting down and talking
with serial medtech entrepreneur Paul Buckman, who at the time,
was CEO of Conventus Orthopedics. 

Prior to Conventus, Paul held CEO roles at SentreHEART, Pathway
Medical Technologies (which sold to Bayer HealthCare), and Devax
(which sold to Biosensors International). From 2004 through 2006,
Buckman served as President of the Cardiology Division of St.
Jude Medical. 

Before joining St. Jude, he served as Chairman and CEO of ev3, a
company that Buckman co-founded and was later acquired by
Covidien for $2.5 billion dollars in 2010.


Paul has worked in the medical device industry for over 35 years,
including 10 years at Scimed Life Systems and Boston Scientific
where he held several executive positions before becoming
President of the Cardiology Division at Boston Scientific in
January of 2000. Buckman received a BA degree in business
administration and an MBA degree from Western Michigan
University. 

Here are a few of the things we’re going to learn in this
interview with Paul:

- Of all the medtech startups that Paul’s been a part of, the two
that are closest to his heart.

- Two of the many key learnings that Paul recalls during his time
helping to build Scimed.

- When it comes to product development for medtech startups, why
it’s critical to be ruthless about prioritization.


See more...